Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines-Reference-Cited by-同舟云学术

Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines

Published:2020-07-23 Issue:8 Volume:14 Page:9904-9916
ISSN:1936-0851
Container-title:ACS Nano
language:en
Short-container-title:ACS Nano

Author:

Shae Daniel¹,Baljon Jessalyn J.²,Wehbe Mohamed¹,Christov Plamen P.³,Becker Kyle W.¹^ORCID,Kumar Amrendra⁴⁵,Suryadevara Naveenchandra⁴⁵,Carson Carcia S.²,Palmer Christian R.¹^ORCID,Knight Frances C.²,Joyce Sebastian⁴⁵⁶⁷^ORCID,Wilson John T.¹²³⁴⁵^ORCID

Affiliation:

1. Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States

2. Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States

3. Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee 37232, United States

4. Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States

5. Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, Tennessee 37212, United States

6. Vanderbilt Institute for Infection, Immunology, and Inflammation, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States

7. Vanderbilt Center for Immunobiology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States

Funder

Vanderbilt University

Vanderbilt-Ingram Cancer Center

Canadian Institutes of Health Research

U.S. Department of Veterans Affairs

National Institute of Dental and Craniofacial Research

National Institute of Allergy and Infectious Diseases

Division of Graduate Education

Stand Up To Cancer

Division of Chemical, Bioengineering, Environmental, and Transport Systems

Publisher

American Chemical Society (ACS)

Subject

General Physics and Astronomy,General Engineering,General Materials Science

Link

https://pubs.acs.org/doi/pdf/10.1021/acsnano.0c02765

Reference71 articles.

1. Cancer immunotherapy using checkpoint blockade

2. The future of immune checkpoint therapy

3. Cancer immunoediting and resistance to T cell-based immunotherapy

4. Understanding the tumor immune microenvironment (TIME) for effective therapy

5. Elements of cancer immunity and the cancer–immune set point

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pickering emulsion-guided monomeric delivery of monophosphoryl lipid A for enhanced vaccination;Journal of Controlled Release;2024-10

2. Dual and multi-immune activation strategies for emerging cancer immunotherapy;Materials Today;2024-09

3. Targeting activation of cGAS-STING signaling pathway by engineered biomaterials for enhancing cancer immunotherapy;Materials Today;2024-09

4. Nanovaccines: Immunogenic tumor antigens, targeted delivery, and combination therapy to enhance cancer immunotherapy;Drug Development Research;2024-08

5. Dostarlimab: A promising new PD-1 inhibitor for cancer immunotherapy;Journal of Oncology Pharmacy Practice;2024-07-26